首页> 外文期刊>Analytical chemistry >Multiplex Immuno-MALDI-TOF MS for Targeted Quantification of Protein Biomarkers and Their Proteoforms Related to Inflammation and Renal Dysfunction
【24h】

Multiplex Immuno-MALDI-TOF MS for Targeted Quantification of Protein Biomarkers and Their Proteoforms Related to Inflammation and Renal Dysfunction

机译:用于蛋白质生物标志物的靶向定量的多重免疫 - MALDI-TOF MS及其与炎症和肾功能紊乱有关的蛋白质常规

获取原文
获取原文并翻译 | 示例
       

摘要

Circulating proteins are widely used as biomarkers in clinical applications for the diagnosis, prediction, and treatment of numerous diseases. Immunoassays are the most common technologies for quantification of protein biomarkers and exist in various formats. Traditional immunoassays offer sensitive and fast analyses but cannot differentiate between proteoforms. Protein microheterogeneity, mainly due to post-translational modification, has been recognized as a fingerprint for different pathologies, and knowledge about proteoforms is an important step toward personalized medicine. Mass spectrometry (MS) has emerged to be a powerful technique for the characterization and quantification of proteoforms. We have established a novel four-plex immunoassay based on Matrix-Assisted Laser Desorption/Ionization Time-Of-Flight (MALDI-TOF) MS for the targeted quantification of the inflammatory markers C-reactive protein (CRP), serum amyloid A (SAA), and calprotectin (S100A8/9) and the kidney function marker cystatin C (CysC). Antibodies were covalently bound to superparamagnetic beads, which delivered robust and fast sample processing. Polyhistidine-tagged recombinant target proteins were used as internal standards for quantification. Our method identified a number of proteoforms for SAA ( n = 11), S100A8/9 ( n = 4) and CysC ( n = 4). The assay was characterized by low limits of detection (0.01?0.06 μg/mL) and low coefficients of variation (3.8–9.4%). Method validation demonstrated good between-assay agreement with immuno-turbidimetry ( R ~(2) = 0.963 for CRP), ELISA ( R ~(2) = 0.958 for SAA; R ~(2) = 0.913 for S100A8/9), and nephelometry ( R ~(2) = 0.963 for CysC). The low sample consumption of 20 μL and the high sample throughput of 384 samples per day make this targeted immuno-MALDI approach suited for assessment of inflammatory and renal status in large cohort studies based on precious biobanks samples.
机译:循环蛋白广泛用作临床应用中的生物标志物,用于诊断,预测和治疗众多疾病的临床应用。免疫测定是用于定量蛋白质生物标志物的最常见技术,并以各种形式存在。传统的免疫大同作用提供敏感和快速的分析,但不能区分蛋白质形式。蛋白质微型物质性,主要是由于翻译后修饰,已被认为是不同病理的指纹,并且关于蛋白质形式的知识是朝着个性化药物的重要一步。质谱(MS)出现是一种强大的技术,用于表征和定量蛋白质Oforms。我们已经建立了基于基于基质辅助激光解吸/电离飞行时间(MALDI-TOF)MS的新型四个Plex免疫测定,用于靶向定量炎症标志物C反应蛋白(CRP),血清淀粉样蛋白A(SAA )和CALPROTECTIN(S100A8 / 9)和肾功能标记胱抑素C(CYSC)。抗体与超顺磁珠共价结合,其提供稳健和快速的样品加工。多亚胺标记的重组靶蛋白被用作定量的内标。我们的方法鉴定了SAA(n = 11),S100a8 / 9(n = 4)和Cysc(n = 4)的许多蛋白质ord。测定的特征在于检测限率低(0.01〜0.06μg/ ml),并且变异的低系数(3.8-9.4%)。方法验证证明了与免疫浊度测定法(R〜(2)= 0.963的CRP)之间的良好 - 酶(R〜(2)= 0.958用于SAA; R〜(2)= 0.913,S100A8 / 9), Nephelometry(Cysc的R〜(2)= 0.963)。每天20μl的低样品消耗量和384样品的高样品吞吐量使得该针对性的免疫马尔德方法适用于基于珍贵的Biobanks样品的大型队列研究中的炎症和肾脏状况评估。

著录项

  • 来源
    《Analytical chemistry》 |2018年第5期|共8页
  • 作者单位

    Department of Clinical Science University of Bergen 5021 Bergen Norway;

    Bevital AS Jonas Lies veg 87 Laboratory Building Ninth Floor 5021 Bergen Norway;

    Institute for Clinical Chemistry and Pathobiochemistry Otto-von-Guericke University Magdeburg Leipziger Strasse 44 39120 Magdeburg Germany;

    Department of Clinical Science University of Bergen 5021 Bergen Norway;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 分析化学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号